Table 2.
Summary of data in the metastatic setting.
| Author (year) | Line of treatment Type of trial |
Drug(s) | Number of patients evaluable for end points | Results |
|---|---|---|---|---|
| Yoshimoto et al. [11] | 1st-2nd line Phase II |
CAPE 828 mg/m2 twice daily + CTX 33 mg/m2 twice daily, dd 1 → 14, every 21 days | 9 | ORR 44.4% CBR 57.8% Median PFS 10.7 months |
|
| ||||
| Wang et al. [12] | 2nd line or further (maintenance) Phase II |
CTX 50 mg daily (after CTX 3 g/m2 for the preparation of CD34+ and CTX 3 g/m2, thiotepa 150 mg/m2, and CBDCA AUC = 6, every 28 dd for 2 courses) | 23 | NA |
|
| ||||
| Kummar et al. [13] | 2nd line or further Phase II |
CTX 50 mg/day versus CTX 50 mg/day + Veliparib 60 mg once daily throughout a 21-day cycle |
39 | ORR 5.6% versus 9.5% (NS) |
ORR = overall response rate; CBR = clinical benefit rate; PFS = progression-free survival; CBDCA = carboplatin.